AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Business Editors & Health/Medical Writers
MINNEAPOLIS--(BW HealthWire)--Dec. 6, 2001
Medtronic, Inc. (NYSE:MDT), announced today that it has agreed to acquire VidaMed, Inc. (Nasdaq:VIDA). VidaMed's TUNA(R)(Transurethral Needle Ablation) system treats benign prostatic hyperplasia (BPH), a non-cancerous condition also known as "enlarged prostate," which affects up to 23 million men worldwide.
The agreement, valued at approximately $326 million in the aggregate, provides that each VidaMed shareholder will receive $7.91 per share in cash upon consummation of the transaction. Completion of the acquisition is subject to customary conditions, including approval by shareholders, and Hart-Scott-Rodino clearance. The companies expect to complete the transaction during the first calendar quarter of 2002. Medtronic has held a minority investment in VidaMed since January 2000.
Banc of America Securities LLC acted as exclusive financial advisor to VidaMed in connection with this transaction.
"The acquisition of VidaMed complements our rapidly growing…
Source: HighBeam Research, Medtronic Agrees to Acquire VidaMed; VidaMed's TUNA System...